Literature DB >> 20512042

Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of 'subsyndromal' anxiety disorder: a randomized, double-blind, placebo controlled trial.

Siegfried Kasper1, Markus Gastpar, Walter E Müller, Hans-Peter Volz, Hans-Jürgen Möller, Angelika Dienel, Sandra Schläfke.   

Abstract

This study was performed to investigate the anxiolytic efficacy of silexan, a new oral lavender oil capsule preparation, in comparison to placebo in primary care. In 27 general and psychiatric practices 221 adults suffering from anxiety disorder not otherwise specified (Diagnostic and Statistical Manual of Mental disorders-IV 300.00 or International Statistical Classification of Diseases and Related Health Problems, Tenth revision F41.9) were randomized to 80 mg/day of a defined, orally administered preparation from Lavandula species or placebo for 10 weeks with visits every 2 weeks. A Hamilton Anxiety Scale (HAMA) total score >or=18 and a total score >5 for the Pittsburgh Sleep Quality Index (PSQI) were required. The primary outcome measures were HAMA and PSQI total score decrease between baseline and week 10. Secondary efficacy measures included the Clinical Global Impressions scale, the Zung Self-rating Anxiety Scale, and the SF-36 Health Survey Questionnaire. Patients treated with silexan showed a total score decrease by 16.0+/-8.3 points (mean+/-SD, 59.3%) for the HAMA and by 5.5+/-4.4 points (44.7%) for the PSQI compared to 9.5+/-9.1 (35.4%) and 3.8+/-4.1 points (30.9%) in the placebo group (P<0.01 one-sided, intention to treat). Silexan was superior to placebo regarding the percentage of responders (76.9 vs. 49.1%, P<0.001) and remitters (60.6 vs. 42.6%, P=0.009). Lavandula oil preparation had a significant beneficial influence on quality and duration of sleep and improved general mental and physical health without causing any unwanted sedative or other drug specific effects. Lavandula oil preparation silexan is both efficacious and safe for the relief of anxiety disorder not otherwise specified. It has a clinically meaningful anxiolytic effect and alleviates anxiety related disturbed sleep.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20512042     DOI: 10.1097/YIC.0b013e32833b3242

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  30 in total

1.  Aroma oil therapy in palliative care: a pilot study with physiological parameters in conscious as well as unconscious patients.

Authors:  Melanie Goepfert; Patrick Liebl; Natalie Herth; Giancarlo Ciarlo; Jens Buentzel; Jutta Huebner
Journal:  J Cancer Res Clin Oncol       Date:  2017-06-20       Impact factor: 4.553

Review 2.  Biological Activities of Essential Oils: From Plant Chemoecology to Traditional Healing Systems.

Authors:  Javad Sharifi-Rad; Antoni Sureda; Gian Carlo Tenore; Maria Daglia; Mehdi Sharifi-Rad; Marco Valussi; Rosa Tundis; Marzieh Sharifi-Rad; Monica R Loizzo; Adedayo Oluwaseun Ademiluyi; Razieh Sharifi-Rad; Seyed Abdulmajid Ayatollahi; Marcello Iriti
Journal:  Molecules       Date:  2017-01-01       Impact factor: 4.411

Review 3.  Herbal medicine for depression and anxiety: A systematic review with assessment of potential psycho-oncologic relevance.

Authors:  K Simon Yeung; Marisol Hernandez; Jun J Mao; Ingrid Haviland; Jyothirmai Gubili
Journal:  Phytother Res       Date:  2018-02-21       Impact factor: 5.878

Review 4.  Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder - evidence from clinical trials.

Authors:  Siegfried Kasper; Markus Gastpar; Walter E Müller; Hans-Peter Volz; Hans-Jürgen Möller; Angelika Dienel; Sandra Schläfke
Journal:  Wien Med Wochenschr       Date:  2010-12

5.  Phytopharmaceutical treatment of anxiety, depression, and dementia in the elderly: evidence from randomized, controlled clinical trials.

Authors:  Siegfried Kasper
Journal:  Wien Med Wochenschr       Date:  2015-06-20

Review 6.  Mood Therapeutics: Novel Pharmacological Approaches for Treating Depression.

Authors:  Ioline D Henter; Rafael T de Sousa; Philip W Gold; Andre R Brunoni; Carlos A Zarate; Rodrigo Machado-Vieira
Journal:  Expert Rev Clin Pharmacol       Date:  2017-01-16       Impact factor: 5.045

Review 7.  Practical clinical trials in psychopharmacology: a systematic review.

Authors:  Benedetto Vitiello
Journal:  J Clin Psychopharmacol       Date:  2015-04       Impact factor: 3.153

8.  Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: randomized, placebo-controlled trials revisited.

Authors:  Lucie Bartova; Markus Dold; Hans-Peter Volz; Erich Seifritz; Hans-Jürgen Möller; Siegfried Kasper
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-03-09       Impact factor: 5.270

9.  The diagnosis and treatment of generalized anxiety disorder.

Authors:  Borwin Bandelow; Reinhard Boerner J; Siegfried Kasper; Michael Linden; Hans-Ulrich Wittchen; Hans-Jürgen Möller
Journal:  Dtsch Arztebl Int       Date:  2013-04-26       Impact factor: 5.594

Review 10.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.